{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T01:17:12Z","timestamp":1791249432565,"version":"4.1.0"},"reference-count":125,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","internationaljournalofcardiology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Cardiology"],"published-print":{"date-parts":[[2016,1]]},"DOI":"10.1016\/j.ijcard.2015.10.033","type":"journal-article","created":{"date-parts":[[2015,10,21]],"date-time":"2015-10-21T05:59:29Z","timestamp":1445407169000},"page":"766-772","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["Loss of muscle mass: Current developments in cachexia and sarcopenia focused on biomarkers and treatment"],"prefix":"10.1016","volume":"202","author":[{"given":"Cathleen","family":"Drescher","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaaki","family":"Konishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Ebner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jochen","family":"Springer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ijcard.2015.10.033_bb0005","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s13539-011-0019-5","article-title":"Wasting in chronic kidney disease","volume":"2","author":"Mak","year":"2011","journal-title":"J. Cachex. Sarcopenia Muscle"},{"issue":"949","key":"10.1016\/j.ijcard.2015.10.033_bb0010","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1136\/pgmj.2004.020891","article-title":"Cachexia in malaria and heart failure: therapeutic considerations in clinical practice","volume":"80","author":"Onwuamaegbu","year":"2004","journal-title":"Postgrad. Med. J."},{"issue":"3","key":"10.1016\/j.ijcard.2015.10.033_bb0015","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.pharmthera.2008.09.009","article-title":"Cardiac cachexia: a systematic overview","volume":"121","author":"von Haehling","year":"2009","journal-title":"Pharmacol. Ther."},{"issue":"5","key":"10.1016\/j.ijcard.2015.10.033_bb0020","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/S1470-2045(10)70218-7","article-title":"Definition and classification of cancer cachexia: an international consensus","volume":"12","author":"Fearon","year":"2011","journal-title":"Lancet Oncol."},{"issue":"6","key":"10.1016\/j.ijcard.2015.10.033_bb0025","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.clnu.2008.06.013","article-title":"Cachexia: a new definition","volume":"27","author":"Evans","year":"2008","journal-title":"Clin. Nutr."},{"issue":"3","key":"10.1016\/j.ijcard.2015.10.033_bb0030","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.cger.2011.03.003","article-title":"Sarcopenia: origins and clinical relevance","volume":"27","author":"Rosenberg","year":"2011","journal-title":"Clin. Geriatr. Med."},{"issue":"8","key":"10.1016\/j.ijcard.2015.10.033_bb0035","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1093\/gerona\/63.8.829","article-title":"Sarcopenia =\/= dynapenia","volume":"63","author":"Clark","year":"2008","journal-title":"J. Gerontol. A Biol. Sci. Med. Sci."},{"issue":"1","key":"10.1016\/j.ijcard.2015.10.033_bb0040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s13539-014-0135-0","article-title":"Muscle wasting disease: a proposal for a new disease classification","volume":"5","author":"Anker","year":"2014","journal-title":"J. Cachex. Sarcopenia Muscle"},{"issue":"3","key":"10.1016\/j.ijcard.2015.10.033_bb0045","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s13539-013-0105-y","article-title":"Cachexia as a major public health problem: frequent, costly, and deadly","volume":"4","author":"Farkas","year":"2013","journal-title":"J. Cachex. Sarcopenia Muscle"},{"key":"10.1016\/j.ijcard.2015.10.033_bb0050","doi-asserted-by":"crossref","first-page":"99","DOI":"10.3389\/fphys.2014.00099","article-title":"Skeletal muscle wasting with disuse atrophy is multi-dimensional: the response and interaction of myonuclei, satellite cells and signaling pathways","volume":"5","author":"Brooks","year":"2014","journal-title":"Front. Physiol."},{"key":"10.1016\/j.ijcard.2015.10.033_bb0055","first-page":"1","article-title":"The wasting continuum in heart failure: from sarcopenia to cachexia","author":"von Haehling","year":"2015","journal-title":"Proc. Nutr. Soc."},{"issue":"3","key":"10.1016\/j.ijcard.2015.10.033_bb0060","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s13539-014-0146-x","article-title":"Osteosarcopenic obesity: the role of bone, muscle, and fat on health","volume":"5","author":"Ormsbee","year":"2014","journal-title":"J. Cachex. Sarcopenia Muscle"},{"issue":"3","key":"10.1016\/j.ijcard.2015.10.033_bb0065","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s13539-013-0108-8","article-title":"Development and relative validity of a new field instrument for detection of geriatric cachexia: preliminary analysis in hip fracture patients","volume":"4","author":"Villani","year":"2013","journal-title":"J. Cachex. Sarcopenia Muscle"},{"issue":"2","key":"10.1016\/j.ijcard.2015.10.033_bb0070","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s13539-013-0111-0","article-title":"Why cachexia kills: examining the causality of poor outcomes in wasting conditions","volume":"4","author":"Kalantar-Zadeh","year":"2013","journal-title":"J. Cachex. Sarcopenia Muscle"},{"issue":"3","key":"10.1016\/j.ijcard.2015.10.033_bb0075","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1097\/MCO.0b013e32833862df","article-title":"Signaling pathways perturbing muscle mass","volume":"13","author":"Glass","year":"2010","journal-title":"Curr. Opin. Clin. Nutr. Metab. Care"},{"issue":"4898","key":"10.1016\/j.ijcard.2015.10.033_bb0080","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1126\/science.2538923","article-title":"A multiubiquitin chain is confined to specific lysine in a targeted short-lived protein","volume":"243","author":"Chau","year":"1989","journal-title":"Science"},{"issue":"11","key":"10.1016\/j.ijcard.2015.10.033_bb0085","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1038\/sj.onc.1207390","article-title":"Role of protein ubiquitylation in regulating endocytosis of receptor tyrosine kinases","volume":"23","author":"Marmor","year":"2004","journal-title":"Oncogene"},{"issue":"Pt 3","key":"10.1016\/j.ijcard.2015.10.033_bb0090","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1042\/bj20040198","article-title":"Getting into position: the catalytic mechanisms of protein ubiquitylation","volume":"379","author":"Passmore","year":"2004","journal-title":"Biochem. J."},{"key":"10.1016\/j.ijcard.2015.10.033_bb0095","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1042\/bse0410173","article-title":"The ubiquitin\u2013proteasome system and skeletal muscle wasting","volume":"41","author":"Attaix","year":"2005","journal-title":"Essays Biochem."},{"issue":"5547","key":"10.1016\/j.ijcard.2015.10.033_bb0100","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1126\/science.1065874","article-title":"Identification of ubiquitin ligases required for skeletal muscle atrophy","volume":"294","author":"Bodine","year":"2001","journal-title":"Science"},{"issue":"25","key":"10.1016\/j.ijcard.2015.10.033_bb0105","doi-asserted-by":"crossref","first-page":"14440","DOI":"10.1073\/pnas.251541198","article-title":"Atrogin-1, a muscle-specific F-box protein highly expressed during muscle atrophy","volume":"98","author":"Gomes","year":"2001","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"4","key":"10.1016\/j.ijcard.2015.10.033_bb0110","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.1074\/jbc.M411346200","article-title":"Degradation of MyoD mediated by the SCF (MAFbx) ubiquitin ligase","volume":"280","author":"Tintignac","year":"2005","journal-title":"J. Biol. Chem."},{"issue":"8","key":"10.1016\/j.ijcard.2015.10.033_bb0115","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1038\/emboj.2008.52","article-title":"The initiation factor eIF3-f is a major target for atrogin1\/MAFbx function in skeletal muscle atrophy","volume":"27","author":"Lagirand-Cantaloube","year":"2008","journal-title":"EMBO J."},{"issue":"4","key":"10.1016\/j.ijcard.2015.10.033_bb0120","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1006\/jmbi.2001.4448","article-title":"Identification of muscle specific ring finger proteins as potential regulators of the titin kinase domain","volume":"306","author":"Centner","year":"2001","journal-title":"J. Mol. Biol."},{"issue":"1","key":"10.1016\/j.ijcard.2015.10.033_bb0125","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1083\/jcb.200108089","article-title":"Muscle-specific RING finger-1 interacts with titin to regulate sarcomeric M-line and thick filament structure and may have nuclear functions via its interaction with glucocorticoid modulatory element binding protein-1","volume":"157","author":"McElhinny","year":"2002","journal-title":"J. Cell Biol."},{"issue":"6","key":"10.1016\/j.ijcard.2015.10.033_bb0130","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1083\/jcb.200901052","article-title":"During muscle atrophy, thick, but not thin, filament components are degraded by MuRF1-dependent ubiquitylation","volume":"185","author":"Cohen","year":"2009","journal-title":"J. Cell Biol."},{"issue":"2","key":"10.1016\/j.ijcard.2015.10.033_bb0135","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.jmb.2005.09.068","article-title":"Trim32 is a ubiquitin ligase mutated in limb girdle muscular dystrophy type 2H that binds to skeletal muscle myosin and ubiquitinates actin","volume":"354","author":"Kudryashova","year":"2005","journal-title":"J. Mol. Biol."},{"issue":"1\u20132","key":"10.1016\/j.ijcard.2015.10.033_bb0140","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.gene.2007.08.020","article-title":"FBXO40, a gene encoding a novel muscle-specific F-box protein, is upregulated in denervation-related muscle atrophy","volume":"404","author":"Ye","year":"2007","journal-title":"Gene"},{"issue":"5","key":"10.1016\/j.ijcard.2015.10.033_bb0145","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.devcel.2011.09.011","article-title":"The SCF-Fbxo40 complex induces IRS1 ubiquitination in skeletal muscle, limiting IGF1 signaling","volume":"21","author":"Shi","year":"2011","journal-title":"Dev. Cell"},{"issue":"7","key":"10.1016\/j.ijcard.2015.10.033_bb0150","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1083\/jcb.201006098","article-title":"Targeted ablation of TRAF6 inhibits skeletal muscle wasting in mice","volume":"191","author":"Paul","year":"2010","journal-title":"J. Cell Biol."},{"issue":"3","key":"10.1016\/j.ijcard.2015.10.033_bb0155","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1172\/JCI200420174","article-title":"Cancer cachexia is regulated by selective targeting of skeletal muscle gene products","volume":"114","author":"Acharyya","year":"2004","journal-title":"J. Clin. Invest."},{"issue":"5","key":"10.1016\/j.ijcard.2015.10.033_bb0160","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1158\/0008-5472.CAN-10-3145","article-title":"Cancer causes cardiac atrophy and autophagy in a sexually dimorphic manner","volume":"71","author":"Cosper","year":"2011","journal-title":"Cancer Res."},{"issue":"7","key":"10.1016\/j.ijcard.2015.10.033_bb0165","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1054\/bjoc.2001.1696","article-title":"Activation of Ca(2+)-dependent proteolysis in skeletal muscle and heart in cancer cachexia","volume":"84","author":"Costelli","year":"2001","journal-title":"Br. J. Cancer"},{"issue":"4","key":"10.1016\/j.ijcard.2015.10.033_bb0170","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s13539-013-0116-8","article-title":"Disruption of pro-oxidant and antioxidant systems with elevated expression of the ubiquitin proteosome system in the cachectic heart muscle of nude mice","volume":"4","author":"Hinch","year":"2013","journal-title":"J. Cachex. Sarcopenia Muscle"},{"issue":"14","key":"10.1016\/j.ijcard.2015.10.033_bb0175","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1093\/eurheartj\/eht302","article-title":"Prevention of liver cancer cachexia-induced cardiac wasting and heart failure","volume":"35","author":"Springer","year":"2014","journal-title":"Eur. Heart J."},{"issue":"1","key":"10.1016\/j.ijcard.2015.10.033_bb0180","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.cardiores.2006.10.026","article-title":"Myocardial expression of Murf-1 and MAFbx after induction of chronic heart failure: effect on myocardial contractility","volume":"73","author":"Adams","year":"2007","journal-title":"Cardiovasc. Res."},{"issue":"2","key":"10.1016\/j.ijcard.2015.10.033_bb0185","first-page":"347","article-title":"Cardiac alterations in cancer-induced cachexia in mice","volume":"37","author":"Tian","year":"2010","journal-title":"Int. J. Oncol."},{"issue":"1","key":"10.1016\/j.ijcard.2015.10.033_bb0190","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0304-3835(02)00006-X","article-title":"Induction of protein catabolism and the ubiquitin\u2013proteasome pathway by mild oxidative stress","volume":"180","author":"Gomes-Marcondes","year":"2002","journal-title":"Cancer Lett."},{"issue":"7","key":"10.1016\/j.ijcard.2015.10.033_bb0195","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1016\/j.febslet.2005.02.017","article-title":"Both oxidative and nitrosative stress are associated with muscle wasting in tumour-bearing rats","volume":"579","author":"Barreiro","year":"2005","journal-title":"FEBS Lett."},{"issue":"1","key":"10.1016\/j.ijcard.2015.10.033_bb0200","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/2044-5040-2-2","article-title":"TNF-alpha- and tumor-induced skeletal muscle atrophy involves sphingolipid metabolism","volume":"2","author":"De Larichaudy","year":"2012","journal-title":"Skelet. Muscle"},{"issue":"6","key":"10.1016\/j.ijcard.2015.10.033_bb0205","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1096\/fj.01-0866com","article-title":"Activation of an alternative NF-kappaB pathway in skeletal muscle during disuse atrophy","volume":"16","author":"Hunter","year":"2002","journal-title":"FASEB J."},{"issue":"2","key":"10.1016\/j.ijcard.2015.10.033_bb0210","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.cell.2004.09.027","article-title":"IKKbeta\/NF-kappaB activation causes severe muscle wasting in mice","volume":"119","author":"Cai","year":"2004","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.ijcard.2015.10.033_bb0215","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1152\/japplphysiol.01202.2006","article-title":"Oxidative stress and disuse muscle atrophy","volume":"102","author":"Powers","year":"2007","journal-title":"J. Appl. Physiol. (1985)"},{"issue":"2","key":"10.1016\/j.ijcard.2015.10.033_bb0220","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s13539-012-0101-7","article-title":"Metabolic derangements in the gastrocnemius and the effect of Compound A therapy in a murine model of cancer cachexia","volume":"4","author":"Der-Torossian","year":"2013","journal-title":"J. Cachex. Sarcopenia Muscle"},{"issue":"3","key":"10.1016\/j.ijcard.2015.10.033_bb0225","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1096\/fj.11-189977","article-title":"Inhibition of FoxO transcriptional activity prevents muscle fiber atrophy during cachexia and induces hypertrophy","volume":"26","author":"Reed","year":"2012","journal-title":"Faseb J"},{"issue":"1","key":"10.1016\/j.ijcard.2015.10.033_bb0230","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0087776","article-title":"C26 cancer-induced muscle wasting is IKKbeta-dependent and NF-kappaB-independent","volume":"9","author":"Cornwell","year":"2014","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ijcard.2015.10.033_bb0235","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1186\/1471-2407-12-265","article-title":"Real-imaging cDNA-AFLP transcript profiling of pancreatic cancer patients: Egr-1 as a potential key regulator of muscle cachexia","volume":"12","author":"Skorokhod","year":"2012","journal-title":"BMC Cancer"},{"issue":"10","key":"10.1016\/j.ijcard.2015.10.033_bb0240","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1038\/emboj.2010.60","article-title":"Mitochondrial fission and remodelling contributes to muscle atrophy","volume":"29","author":"Romanello","year":"2010","journal-title":"EMBO J."},{"issue":"1","key":"10.1016\/j.ijcard.2015.10.033_bb0245","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s13539-012-0073-7","article-title":"Effect of colon cancer and surgical resection on skeletal muscle mitochondrial enzyme activity in colon cancer patients: a pilot study","volume":"4","author":"Phillips","year":"2013","journal-title":"J. Cachex. Sarcopenia Muscle"},{"issue":"1","key":"10.1016\/j.ijcard.2015.10.033_bb0250","doi-asserted-by":"crossref","first-page":"e72","DOI":"10.1111\/j.1600-0838.2009.00900.x","article-title":"Morphological changes in hind limb muscles elicited by adjuvant-induced arthritis of the rat knee","volume":"20","author":"Ozawa","year":"2010","journal-title":"Scand. J. Med. Sci. Sports"},{"key":"10.1016\/j.ijcard.2015.10.033_bb0255","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/1471-2474-10-59","article-title":"Locomotion and muscle mass measures in a murine model of collagen-induced arthritis","volume":"10","author":"Hartog","year":"2009","journal-title":"BMC Musculoskelet. Disord."},{"key":"10.1016\/j.ijcard.2015.10.033_bb0260","series-title":"Pathological and molecular changes in skeletal muscle of collagen induced arthritis","author":"Teixeira","year":"2011"},{"issue":"3","key":"10.1016\/j.ijcard.2015.10.033_bb0265","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s13539-013-0102-1","article-title":"Temporal development of muscle atrophy in murine model of arthritis is related to disease severity","volume":"4","author":"Filippin","year":"2013","journal-title":"J. Cachex. Sarcopenia Muscle"},{"issue":"2","key":"10.1016\/j.ijcard.2015.10.033_bb0270","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ijcard.2013.10.031","article-title":"Stroke induced sarcopenia: muscle wasting and disability after stroke","volume":"170","author":"Scherbakov","year":"2013","journal-title":"Int. J. Cardiol."},{"issue":"3","key":"10.1016\/j.ijcard.2015.10.033_bb0275","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s13539-013-0103-0","article-title":"Investigation of changes in body composition, metabolic profile and skeletal muscle functional capacity in ischemic stroke patients: the rationale and design of the Body Size in Stroke Study (BoSSS)","volume":"4","author":"Knops","year":"2013","journal-title":"J. Cachex. Sarcopenia Muscle"},{"issue":"6","key":"10.1016\/j.ijcard.2015.10.033_bb0280","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1079\/BJN19980085","article-title":"Nutritional status of hospitalized acute stroke patients","volume":"79","author":"Gariballa","year":"1998","journal-title":"Br. J. Nutr."},{"issue":"1","key":"10.1016\/j.ijcard.2015.10.033_bb0285","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1001\/archneurol.2007.12","article-title":"Undernutrition as a predictor of poor clinical outcomes in acute ischemic stroke patients","volume":"65","author":"Yoo","year":"2008","journal-title":"Arch. Neurol."},{"issue":"3","key":"10.1016\/j.ijcard.2015.10.033_bb0290","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1159\/000090792","article-title":"Longitudinal changes in muscle strength and mass after acute stroke","volume":"21","author":"Carin-Levy","year":"2006","journal-title":"Cerebrovasc. Dis."},{"issue":"6","key":"10.1016\/j.ijcard.2015.10.033_bb0295","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/S8756-3282(01)00434-3","article-title":"Changes in muscle mass, fat mass, and bone mineral content in the legs after stroke: a 1year prospective study","volume":"28","author":"Jorgensen","year":"2001","journal-title":"Bone"},{"issue":"9","key":"10.1016\/j.ijcard.2015.10.033_bb0300","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1161\/01.STR.0000177878.33559.fe","article-title":"Elevated tumor necrosis factor-alpha in skeletal muscle after stroke","volume":"36","author":"Hafer-Macko","year":"2005","journal-title":"Stroke"},{"issue":"5","key":"10.1016\/j.ijcard.2015.10.033_bb0305","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.jstrokecerebrovasdis.2009.01.003","article-title":"Elevated visfatin\/pre-B-cell colony-enhancing factor plasma concentration in ischemic stroke","volume":"18","author":"Lu","year":"2009","journal-title":"J. Stroke Cerebrovasc. Dis."},{"issue":"1","key":"10.1016\/j.ijcard.2015.10.033_bb0310","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s13539-014-0130-5","article-title":"Assessing skeletal muscle mass: historical overview and state of the art","volume":"5","author":"Heymsfield","year":"2014","journal-title":"J. Cachex. Sarcopenia Muscle"},{"issue":"3","key":"10.1016\/j.ijcard.2015.10.033_bb0315","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s13539-012-0081-7","article-title":"Finding good biomarkers for sarcopenia","volume":"3","author":"Scharf","year":"2012","journal-title":"J. Cachex. Sarcopenia Muscle"},{"issue":"3","key":"10.1016\/j.ijcard.2015.10.033_bb0320","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s13539-012-0078-2","article-title":"Biomarkers of sarcopenia in clinical trials\u2014recommendations from the International Working Group on Sarcopenia","volume":"3","author":"Cesari","year":"2012","journal-title":"J. Cachex. Sarcopenia Muscle"},{"issue":"3","key":"10.1016\/j.ijcard.2015.10.033_bb0325","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s13539-013-0107-9","article-title":"Development of a practical screening tool to predict low muscle mass using NHANES 1999\u20132004","volume":"4","author":"Goodman","year":"2013","journal-title":"J. Cachex. Sarcopenia Muscle"},{"issue":"1","key":"10.1016\/j.ijcard.2015.10.033_bb0330","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s13539-012-0079-1","article-title":"Serum creatinine as a marker of muscle mass in chronic kidney disease: results of a cross-sectional study and review of literature","volume":"4","author":"Patel","year":"2013","journal-title":"J. Cachex. Sarcopenia Muscle"},{"issue":"11","key":"10.1016\/j.ijcard.2015.10.033_bb0335","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1152\/japplphysiol.00122.2012","article-title":"Total-body creatine pool size and skeletal muscle mass determination by creatine-(methyl-D3) dilution in rats","volume":"112","author":"Stimpson","year":"2012","journal-title":"J. Appl. Physiol."},{"issue":"3","key":"10.1016\/j.ijcard.2015.10.033_bb0340","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s13539-013-0110-1","article-title":"Longitudinal changes in total body creatine pool size and skeletal muscle mass using the D-creatine dilution method","volume":"4","author":"Stimpson","year":"2013","journal-title":"J. Cachex. Sarcopenia Muscle"},{"issue":"1","key":"10.1016\/j.ijcard.2015.10.033_bb0345","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s13539-012-0086-2","article-title":"Serological muscle loss biomarkers: an overview of current concepts and future possibilities","volume":"4","author":"Nedergaard","year":"2013","journal-title":"J. Cachex. Sarcopenia Muscle"},{"issue":"4","key":"10.1016\/j.ijcard.2015.10.033_bb0350","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s13539-013-0114-x","article-title":"Type VI collagen turnover-related peptides\u2014novel serological biomarkers of muscle mass and anabolic response to loading in young men","volume":"4","author":"Nedergaard","year":"2013","journal-title":"J. Cachex. Sarcopenia Muscle"},{"issue":"2","key":"10.1016\/j.ijcard.2015.10.033_bb0355","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s13539-013-0120-z","article-title":"Biomarkers of muscle quality: N-terminal propeptide of type III procollagen and C-terminal agrin fragment responses to resistance exercise training in older adults","volume":"5","author":"Fragala","year":"2013","journal-title":"J. Cachex. Sarcopenia Muscle"},{"issue":"11","key":"10.1016\/j.ijcard.2015.10.033_bb0360","doi-asserted-by":"crossref","first-page":"4224","DOI":"10.1210\/jc.2009-1434","article-title":"N-terminal propeptide of type III procollagen as a biomarker of anabolic response to recombinant human GH and testosterone","volume":"94","author":"Bhasin","year":"2009","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"9","key":"10.1016\/j.ijcard.2015.10.033_bb0365","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1073\/pnas.70.9.2687","article-title":"Complete amino-acid sequence of actin of rabbit skeletal muscle","volume":"70","author":"Elzinga","year":"1973","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"2","key":"10.1016\/j.ijcard.2015.10.033_bb0370","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1021\/bi00778a006","article-title":"Amino acid sequence around the single 3-methylhistidine residue in rabbit skeletal muscle myosin","volume":"10","author":"Huszar","year":"1971","journal-title":"Biochemistry"},{"issue":"5","key":"10.1016\/j.ijcard.2015.10.033_bb0375","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/0026-0495(78)90018-5","article-title":"Muscle protein breakdown rates in humans based on Ntau-methylhistidine (3-methylhistidine) content of mixed proteins in skeletal muscle and urinary output of Ntau-methylhistidine","volume":"27","author":"Bilmazes","year":"1978","journal-title":"Metabolism"},{"issue":"9","key":"10.1016\/j.ijcard.2015.10.033_bb0380","first-page":"2291","article-title":"Ntau-methylhistidine (3-methylhistidine) and muscle protein turnover: an overview","volume":"37","author":"Young","year":"1978","journal-title":"Fed. Proc."},{"issue":"1","key":"10.1016\/j.ijcard.2015.10.033_bb0385","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s13539-013-0117-7","article-title":"Isotopic decay of urinary or plasma 3-methylhistidine as a potential biomarker of pathologic skeletal muscle loss","volume":"5","author":"Sheffield-Moore","year":"2013","journal-title":"J. Cachex. Sarcopenia Muscle"},{"issue":"1","key":"10.1016\/j.ijcard.2015.10.033_bb0390","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s13539-014-0136-z","article-title":"Highlights from the 7th Cachexia Conference: muscle wasting pathophysiological detection and novel treatment strategies","volume":"5","author":"Ebner","year":"2014","journal-title":"J. Cachex. Sarcopenia Muscle"},{"issue":"4","key":"10.1016\/j.ijcard.2015.10.033_bb0395","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s13539-013-0123-9","article-title":"Abstracts of the 7th Cachexia Conference, Kobe\/Osaka, Japan, December 9\u201311, 2013","volume":"4","year":"2013","journal-title":"J. Cachex. Sarcopenia Muscle"},{"issue":"3","key":"10.1016\/j.ijcard.2015.10.033_bb0400","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1007\/s12020-012-9836-3","article-title":"Prevalence of cachexia in chronic heart failure and characteristics of body composition and metabolic status","volume":"43","author":"Christensen","year":"2013","journal-title":"Endocrine"},{"key":"10.1016\/j.ijcard.2015.10.033_bb0405","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.arr.2015.05.001","article-title":"Sarcopenia \u2014 the search for emerging biomarkers","volume":"22","author":"Kalinkovich","year":"2015","journal-title":"Ageing Res. Rev."},{"issue":"43","key":"10.1016\/j.ijcard.2015.10.033_bb0410","doi-asserted-by":"crossref","first-page":"40735","DOI":"10.1074\/jbc.M206379200","article-title":"The myostatin propeptide and the follistatin-related gene are inhibitory binding proteins of myostatin in normal serum","volume":"277","author":"Hill","year":"2002","journal-title":"J. Biol. Chem."},{"issue":"16","key":"10.1016\/j.ijcard.2015.10.033_bb0415","doi-asserted-by":"crossref","first-page":"9306","DOI":"10.1073\/pnas.151270098","article-title":"Regulation of myostatin activity and muscle growth","volume":"98","author":"Lee","year":"2001","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"7382","key":"10.1016\/j.ijcard.2015.10.033_bb0420","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/nature10777","article-title":"A PGC1-alpha-dependent myokine that drives brown-fat-like development of white fat and thermogenesis","volume":"481","author":"Bostrom","year":"2012","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.ijcard.2015.10.033_bb0425","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1530\/EJE-13-0276","article-title":"Irisin mRNA and circulating levels in relation to other myokines in healthy and morbidly obese humans","volume":"169","author":"Vamvini","year":"2013","journal-title":"Eur. J. Endocrinol."},{"issue":"2","key":"10.1016\/j.ijcard.2015.10.033_bb0430","doi-asserted-by":"crossref","first-page":"72","DOI":"10.3322\/canjclin.52.2.72","article-title":"Cancer anorexia\u2013cachexia syndrome: current issues in research and management","volume":"52","author":"Inui","year":"2002","journal-title":"CA Cancer J. Clin."},{"issue":"3","key":"10.1016\/j.ijcard.2015.10.033_bb0435","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1097\/01.mco.0000165004.93707.88","article-title":"Systemic inflammation, cachexia and prognosis in patients with cancer","volume":"8","author":"Deans","year":"2005","journal-title":"Curr. Opin. Clin. Nutr. Metab. Care"},{"issue":"5","key":"10.1016\/j.ijcard.2015.10.033_bb0440","doi-asserted-by":"crossref","first-page":"2920","DOI":"10.1210\/jc.2004-1788","article-title":"Active ghrelin levels and active to total ghrelin ratio in cancer-induced cachexia","volume":"90","author":"Garcia","year":"2005","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"1","key":"10.1016\/j.ijcard.2015.10.033_bb0445","first-page":"40","article-title":"Effects of intra-VMN mianserin and IL-1ra on meal number in anorectic tumor-bearing rats","volume":"48","author":"Laviano","year":"2000","journal-title":"J. Investig. Med."},{"issue":"10","key":"10.1016\/j.ijcard.2015.10.033_bb0450","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1007\/s001090000137","article-title":"Serum levels of leptin and proinflammatory cytokines in patients with advanced-stage cancer at different sites","volume":"78","author":"Mantovani","year":"2000","journal-title":"J. Mol. Med. (Berl)"},{"issue":"6","key":"10.1016\/j.ijcard.2015.10.033_bb0455","doi-asserted-by":"crossref","first-page":"2832","DOI":"10.1210\/jc.2003-031768","article-title":"Ghrelin increases energy intake in cancer patients with impaired appetite: acute, randomized, placebo-controlled trial","volume":"89","author":"Neary","year":"2004","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"2\u20134","key":"10.1016\/j.ijcard.2015.10.033_bb0460","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1159\/000334106","article-title":"Obestatin: an interesting but controversial gut hormone","volume":"59","author":"Lacquaniti","year":"2011","journal-title":"Ann. Nutr. Metab."},{"key":"10.1016\/j.ijcard.2015.10.033_bb0465","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1186\/1471-2407-14-828","article-title":"Emerging markers of cachexia predict survival in cancer patients","volume":"14","author":"Mondello","year":"2014","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.ijcard.2015.10.033_bb0470","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1002\/jcsm.12005","article-title":"Evaluating potential biomarkers of cachexia and survival in skeletal muscle of upper gastrointestinal cancer patients","volume":"6","author":"Stephens","year":"2015","journal-title":"J. Cachex. Sarcopenia Muscle"},{"issue":"1","key":"10.1016\/j.ijcard.2015.10.033_bb0475","first-page":"325","article-title":"The correlation between a chronic inflammatory marker tartrate-resistant acid phosphatase 5a with cancer cachexia","volume":"20","author":"Wu","year":"2015","journal-title":"J. BUON"},{"issue":"1\u20132","key":"10.1016\/j.ijcard.2015.10.033_bb0480","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0009-8981(02)00026-8","article-title":"Serum tartrate-resistant acid phosphatase isoforms in rheumatoid arthritis","volume":"320","author":"Janckila","year":"2002","journal-title":"Clin. Chim. Acta"},{"issue":"11\u201312","key":"10.1016\/j.ijcard.2015.10.033_bb0485","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/j.cca.2011.01.035","article-title":"Serum tartrate-resistant acid phosphatase isoform 5a (TRACP5a) as a potential risk marker in cardiovascular disease","volume":"412","author":"Janckila","year":"2011","journal-title":"Clin. Chim. Acta"},{"issue":"6","key":"10.1016\/j.ijcard.2015.10.033_bb0490","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.jfma.2012.07.033","article-title":"Tartrate-resistant acid phosphatase 5a in sarcoidosis: further evidence for a novel macrophage biomarker in chronic inflammation","volume":"113","author":"Wu","year":"2014","journal-title":"J. Formos. Med. Assoc."},{"issue":"1","key":"10.1016\/j.ijcard.2015.10.033_bb0495","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s13539-014-0129-y","article-title":"Abstracts of the 7th Cachexia Conference, Kobe\/Osaka, Japan, December 9\u201311, 2013 (Part 2)","volume":"5","year":"2014","journal-title":"J. Cachex. Sarcopenia Muscle"},{"issue":"2","key":"10.1016\/j.ijcard.2015.10.033_bb0500","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s13539-012-0087-1","article-title":"Cancer cachexia: impact, mechanisms and emerging treatments","volume":"4","author":"Vaughan","year":"2013","journal-title":"J. Cachex. Sarcopenia Muscle"},{"issue":"2","key":"10.1016\/j.ijcard.2015.10.033_bb0505","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s13539-014-0149-7","article-title":"Are we closer to having drugs to treat muscle wasting disease?","volume":"5","author":"Morley","year":"2014","journal-title":"J. Cachex. Sarcopenia Muscle"},{"issue":"2","key":"10.1016\/j.ijcard.2015.10.033_bb0510","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s13539-012-0067-5","article-title":"Are there any benefits of exercise training in cancer cachexia?","volume":"3","author":"Argiles","year":"2012","journal-title":"J. Cachex. Sarcopenia Muscle"},{"issue":"8","key":"10.1016\/j.ijcard.2015.10.033_bb0515","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.jamda.2013.04.008","article-title":"New strategies for the concurrent strength-, power-, and endurance-training prescription in elderly individuals","volume":"14","author":"Cadore","year":"2013","journal-title":"J. Am. Med. Dir. Assoc."},{"issue":"4","key":"10.1016\/j.ijcard.2015.10.033_bb0520","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s13539-012-0090-6","article-title":"Research on cachexia, sarcopenia and skeletal muscle in cardiology","volume":"3","author":"Coats","year":"2012","journal-title":"J. Cachex. Sarcopenia Muscle"},{"issue":"2","key":"10.1016\/j.ijcard.2015.10.033_bb0525","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s13539-012-0096-0","article-title":"Cancer cachexia prevention via physical exercise: molecular mechanisms","volume":"4","author":"Gould","year":"2013","journal-title":"J. Cachex. Sarcopenia Muscle"},{"issue":"9","key":"10.1016\/j.ijcard.2015.10.033_bb0530","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.jamda.2013.05.015","article-title":"Exercise for falls and fracture prevention in long term care facilities: a systematic review and meta-analysis","volume":"14","author":"Silva","year":"2013","journal-title":"J. Am. Med. Dir. Assoc."},{"issue":"4","key":"10.1016\/j.ijcard.2015.10.033_bb0535","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s13539-012-0089-z","article-title":"From muscle wasting to sarcopenia and myopenia: update 2012","volume":"3","author":"von Haehling","year":"2012","journal-title":"J. Cachex. Sarcopenia Muscle"},{"key":"10.1016\/j.ijcard.2015.10.033_bb0540","doi-asserted-by":"crossref","first-page":"569194","DOI":"10.4061\/2011\/569194","article-title":"The effectiveness of exercise interventions for the management of frailty: a systematic review","volume":"2011","author":"Theou","year":"2011","journal-title":"J. Aging Res."},{"issue":"3","key":"10.1016\/j.ijcard.2015.10.033_bb0545","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s13539-014-0143-0","article-title":"Identifying recreational physical activities associated with muscle quality in men and women aged 50years and over","volume":"5","author":"Barbat-Artigas","year":"2014","journal-title":"J. Cachex. Sarcopenia Muscle"},{"issue":"35","key":"10.1016\/j.ijcard.2015.10.033_bb0550","doi-asserted-by":"crossref","first-page":"24896","DOI":"10.1074\/jbc.274.35.24896","article-title":"Insulin and exercise decrease glycogen synthase kinase-3 activity by different mechanisms in rat skeletal muscle","volume":"274","author":"Markuns","year":"1999","journal-title":"J. Biol. Chem."},{"issue":"6","key":"10.1016\/j.ijcard.2015.10.033_bb0555","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/nrd1415","article-title":"GSK3 inhibitors: development and therapeutic potential","volume":"3","author":"Cohen","year":"2004","journal-title":"Nat. Rev. Drug Discov."},{"issue":"Pt 1","key":"10.1016\/j.ijcard.2015.10.033_bb0560","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1042\/bj20031259","article-title":"Further evidence that the tyrosine phosphorylation of glycogen synthase kinase-3 (GSK3) in mammalian cells is an autophosphorylation event","volume":"377","author":"Cole","year":"2004","journal-title":"Biochem. J."},{"issue":"6","key":"10.1016\/j.ijcard.2015.10.033_bb0565","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/S0092-8674(01)00374-9","article-title":"Crystal structure of glycogen synthase kinase 3 beta: structural basis for phosphate-primed substrate specificity and autoinhibition","volume":"105","author":"Dajani","year":"2001","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.ijcard.2015.10.033_bb0570","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1002\/j.1460-2075.1993.tb05715.x","article-title":"Modulation of the glycogen synthase kinase-3 family by tyrosine phosphorylation","volume":"12","author":"Hughes","year":"1993","journal-title":"EMBO J."},{"issue":"4","key":"10.1016\/j.ijcard.2015.10.033_bb0575","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.molcel.2006.10.009","article-title":"A chaperone-dependent GSK3beta transitional intermediate mediates activation-loop autophosphorylation","volume":"24","author":"Lochhead","year":"2006","journal-title":"Mol. Cell"},{"issue":"6559","key":"10.1016\/j.ijcard.2015.10.033_bb0580","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1038\/378785a0","article-title":"Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B","volume":"378","author":"Cross","year":"1995","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.ijcard.2015.10.033_bb0585","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/nrd4467","article-title":"Muscle wasting in disease: molecular mechanisms and promising therapies","volume":"14","author":"Cohen","year":"2015","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ijcard.2015.10.033_bb0590","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.phrs.2015.05.010","article-title":"Skeletal muscle atrophy: potential therapeutic agents and their mechanisms of action","volume":"99","author":"Dutt","year":"2015","journal-title":"Pharmacol. Res."},{"issue":"1","key":"10.1016\/j.ijcard.2015.10.033_bb0595","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s13539-012-0085-3","article-title":"Effect of ghrelin and its analogues, BIM-28131 and BIM-28125, on the expression of myostatin in a rat heart failure model","volume":"4","author":"Lenk","year":"2013","journal-title":"J. Cachex. Sarcopenia Muscle"},{"issue":"4","key":"10.1016\/j.ijcard.2015.10.033_bb0600","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s13539-014-0159-5","article-title":"Anamorelin HCl (ONO-7643), a novel ghrelin receptor agonist, for the treatment of cancer anorexia\u2013cachexia syndrome: preclinical profile","volume":"5","author":"Pietra","year":"2014","journal-title":"J. Cachex. Sarcopenia Muscle"},{"issue":"2","key":"10.1016\/j.ijcard.2015.10.033_bb0605","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s13539-013-0125-7","article-title":"The anabolic catabolic transforming agent (ACTA) espindolol increases muscle mass and decreases fat mass in old rats","volume":"5","author":"Potsch","year":"2014","journal-title":"J. Cachex. Sarcopenia Muscle"},{"issue":"4","key":"10.1016\/j.ijcard.2015.10.033_bb0610","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s13539-011-0046-2","volume":"2","author":"Stewart Coats","year":"2011","journal-title":"J. Cachex. Sarcopenia Muscle"},{"issue":"4","key":"10.1016\/j.ijcard.2015.10.033_bb0615","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s13539-014-0153-y","article-title":"Formoterol in the treatment of experimental cancer cachexia: effects on heart function","volume":"5","author":"Toledo","year":"2014","journal-title":"J. Cachex. Sarcopenia Muscle"},{"issue":"4","key":"10.1016\/j.ijcard.2015.10.033_bb0620","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s13539-014-0139-9","article-title":"Attenuation of muscle wasting in murine C2C 12 myotubes by epigallocatechin-3-gallate","volume":"5","author":"Mirza","year":"2014","journal-title":"J. Cachex. Sarcopenia Muscle"},{"issue":"1","key":"10.1016\/j.ijcard.2015.10.033_bb0625","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.canlet.2011.02.023","article-title":"Epigallocatechin-3-gallate effectively attenuates skeletal muscle atrophy caused by cancer cachexia","volume":"305","author":"Wang","year":"2011","journal-title":"Cancer Lett."}],"container-title":["International Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527315305982?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527315305982?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T17:55:58Z","timestamp":1738000558000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167527315305982"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1]]},"references-count":125,"alternative-id":["S0167527315305982"],"URL":"https:\/\/doi.org\/10.1016\/j.ijcard.2015.10.033","relation":{},"ISSN":["0167-5273"],"issn-type":[{"value":"0167-5273","type":"print"}],"subject":[],"published":{"date-parts":[[2016,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Loss of muscle mass: Current developments in cachexia and sarcopenia focused on biomarkers and treatment","name":"articletitle","label":"Article Title"},{"value":"International Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijcard.2015.10.033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ireland Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}